Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | INVAC-1 |
Synonyms | |
Therapy Description |
INVAC-1 is a cancer vaccine comprised of a DNA plasmid engineered to encode a catalytically inactive human TERT (hTERT) linked to ubiquitin for rapid proteosomal degradation, which potentially induces an anti-tumor immune response and cytotoxicity against TERT-expressing cancer cells and delays tumor growth (PMID: 27141336, PMID: 31558479). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
INVAC-1 | INVAC-1 is a cancer vaccine comprised of a DNA plasmid engineered to encode a catalytically inactive human TERT (hTERT) linked to ubiquitin for rapid proteosomal degradation, which potentially induces an anti-tumor immune response and cytotoxicity against TERT-expressing cancer cells and delays tumor growth (PMID: 27141336, PMID: 31558479). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03265717 | Phase II | INVAC-1 | DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia | Terminated | USA | 0 |